[Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
Takeuchi
Tsutomu
T
Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School.
D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000075202:Contraindications; D006801:Humans; D000069285:Infliximab; D017410:Practice Guidelines as Topic; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab